COPD is a comorbid condition often associated with type 2 diabetes (T2D) and cardiovascular diseases, but few studies have observed the impact of various antidiabetic drugs in patients with COPD and T2D.
We conducted this study to investigate the long-term outcomes of dipeptidyl peptidase-4 (DPP-4) inhibitor use in patients with COPD and T2D.
